COVID-19 vaccine trials in Africa

On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant t...

Full description

Autores:
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13208
Acceso en línea:
https://www.sciencedirect.com/science/article/pii/S221326002030401X
http://hdl.handle.net/20.500.12010/13208
https://doi.org/10.1016/S2213-2600(20)30401-X
Palabra clave:
COVID-19
Vaccines
COVID-19
Rights
License
Acceso restringido
Description
Summary:On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant towards the trial was awarded to Novavax by the Bill & Melinda Gates Foundation. 2665 healthy adults and nearly 240 medically stable, HIV-positive adults will be enrolled.